Drug Trial Radar · NCT06310967
A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 12, 2024
Primary completion
Jul 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- Intelligem Therapeutics Australia Pty Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/II clinical study to evaluate the safety, tolerability, PK, and efficacy of IG3018 tablet in hyperuricemia (HUA) subjects with or without CKD.
Conditions
- Hyperuricemia
- Hypouricemia, Renal
Interventions
IG3018Drug
Oral administration
Placebo matching IG3018Other
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Assessments (Part 1 and Part 2)Time frame: Baseline through study completion at up to 46 days
- The proportions of change from baseline in serum uric acid to normal level (≤ 0.36 mmol/L) (Part 1 and Part 2)Time frame: 4 weeks
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Emeritus Research Pty Ltd -Sydney
Botany, New South Wales, Australia · Recruiting
Pendlebury Research Pty Ltd T/A Novatrials
Kotara, New South Wales, Australia · Recruiting
Emeritus Research Pty Ltd -Melbourne
Camberwell, Victoria, Australia · Recruiting
Chung Shan Medical University Hospital
Taichung, Taiwan, Taiwan · Recruiting
Taipei Medical University Hospital
Taipei, Taiwan, Taiwan · Recruiting
Chang Gung Memorial Hospital
Taoyuan, Taiwan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.